Study of IBI363 for first-line advanced gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called IBI363 in patients with advanced gastric or gastroesophageal junction cancer who have not yet received any treatment. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be advanced or metastatic (spread) and cannot be removed by surgery, and you must not have received any prior systemic treatment (like chemotherapy) for this cancer.
- You must have at least one tumor that can be measured on scans (like CT or MRI).
- You must be in good physical condition (able to do light work or your usual activities) with an ECOG status of 0 or 1.
- You must have a life expectancy of at least 3 months.
- You cannot be pregnant or breastfeeding, and must agree not to become pregnant for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called IBI363 given before and after surgery for people with a certain type of advanced stomach cancer that lacks the MHC-II marker. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
This trial tests a new combination of IBI343, sintilimab, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. It's for those whose tumors are CLDN18.2-positive and not HER2-positive.
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
This trial tests a new combination therapy called IBI363 for people with advanced solid tumors that have stopped responding to standard treatments. It includes two groups: people with EGFR-mutated non-small cell lung cancer or ovarian cancer that has returned.
Hear when a new IBI363 + Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.